Skip to main content
British Heart Journal logoLink to British Heart Journal
. 1995 Jan;73(1):73–75. doi: 10.1136/hrt.73.1.73

Haemochromatosis presenting as congestive cardiac failure.

J Porter 1, N Cary 1, P Schofield 1
PMCID: PMC483760  PMID: 7888267

Abstract

A 24 year old man with congestive cardiac failure was found to have grossly increased transferrin saturations, raised serum ferritin, and an iron-laden myocardium on biopsy. Initial treatment with the iron chelator desferrioxamine was replaced by weekly venesection. He was placed on the cardiac transplant list because of severe left ventricular dysfunction but was later removed because his symptoms and function improved. He remains well with few symptoms and is maintained on regular venesection and testosterone injections.

Full text

PDF
73

Images in this article

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bomford A., Williams R. Long term results of venesection therapy in idiopathic haemochromatosis. Q J Med. 1976 Oct;45(180):611–623. [PubMed] [Google Scholar]
  2. Candell-Riera J., Lu L., Serés L., González J. B., Batlle J., Permanyer-Miralda G., García-del-Castillo H., Soler-Soler J. Cardiac hemochromatosis: beneficial effects of iron removal therapy. An echocardiographic study. Am J Cardiol. 1983 Oct 1;52(7):824–829. doi: 10.1016/0002-9149(83)90422-8. [DOI] [PubMed] [Google Scholar]
  3. Cox T. M. Haemochromatosis. Blood Rev. 1990 Jun;4(2):75–87. doi: 10.1016/0268-960x(90)90030-v. [DOI] [PubMed] [Google Scholar]
  4. Cox T. M., Lord D. K. Hereditary haemochromatosis. Eur J Haematol. 1989 Feb;42(2):113–125. doi: 10.1111/j.1600-0609.1989.tb01200.x. [DOI] [PubMed] [Google Scholar]
  5. Davies S. C., Marcus R. E., Hungerford J. L., Miller M. H., Arden G. B., Huehns E. R. Ocular toxicity of high-dose intravenous desferrioxamine. Lancet. 1983 Jul 23;2(8343):181–184. doi: 10.1016/s0140-6736(83)90170-8. [DOI] [PubMed] [Google Scholar]
  6. FINCH S. C., FINCH C. A. Idiopathic hemochromatosis, an iron storage disease. A. Iron metabolism in hemochromatosis. Medicine (Baltimore) 1955 Dec;34(4):381–430. doi: 10.1097/00005792-195512000-00001. [DOI] [PubMed] [Google Scholar]
  7. Marcus R. E., Davies S. C., Bantock H. M., Underwood S. R., Walton S., Huehns E. R. Desferrioxamine to improve cardiac function in iron-overloaded patients with thalassemia major. Lancet. 1984 Feb 18;1(8373):392–393. doi: 10.1016/s0140-6736(84)90439-2. [DOI] [PubMed] [Google Scholar]
  8. Nichols G. M., Bacon B. R. Hereditary hemochromatosis: pathogenesis and clinical features of a common disease. Am J Gastroenterol. 1989 Aug;84(8):851–862. [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES